GlassScriptPhysician profile
Steven Lawrence Paris
NPI 1629622071
$10,483.74
in general payments reported to CMS, 2019-2025
27 companies · $5,938 in 2025
The $5,938 reported for 2025 was more than what 99% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $426 · 2022: $412 · 2023: $930 · 2024: $2,777 · 2025: $5,938.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,104 · Travel and Lodging: $2,041 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,103.83 |
| Travel and Lodging | $2,041.34 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $2,712.03 | 2023-2025 | Pifeltro, Delstrigo, Capvaxive |
| Gilead Sciences, INC. | $2,638.88 | 2021-2025 | Biktarvy, Yeztugo, Descovy |
| Viiv Healthcare Company | $2,570.48 | 2021-2025 | Apretude, Dovato, Cabenuva |
| Theratechnologies INC. | $628.58 | 2024-2025 | Egrifta, Trogarzo |
| Novo Nordisk INC | $440.46 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $210.87 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $199.46 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $105.62 | 2024-2025 | |
| Harmony Biosciences LLC | $105.57 | 2024 | |
| Pfizer INC. | $104.89 | 2023-2025 | |
| Emd Serono, INC. | $99.31 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.82 | 2024-2025 | Trintellix |
| Glaxosmithkline, LLC. | $93.64 | 2024-2025 | Trelegy Ellipta |
| Organon LLC | $80.77 | 2023 | Nexplanon |
| Amgen INC. | $67.03 | 2023-2025 | Repatha, Otezla, Repatha |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $54.51 | 2024-2025 | Aptima |
| Axsome Therapeutics, INC. | $43.07 | 2024-2025 | Auvelity, Sunosi |
| Halozyme INC | $35.15 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.69 | 2025 | Xifaxan |
| Exact Sciences Corporation | $28.65 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $23.53 | 2024 | Dexcom G6 Transmitter |
| Tms Neurohealth Centers INC. | $22.91 | 2025 | Tms Neurohealth Centers INC. |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.81 | 2025 | Jardiance |
| Tolmar, INC. | $18.78 | 2025 | Jatenzo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.60 | 2025 | Caplyta |
| Antares Pharma, INC. | $18.02 | 2023 | Xyosted, Tlando, Nocdurna |
| Janssen Pharmaceuticals, INC | $13.61 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Paris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.